Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILLUMINATE-C: Lumasiran in Advanced Primary Hyperoxaluria Type 1
2019-001346-17Phase 3Active
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jul 2019
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lumasiran in Primary Hyperoxaluria Type 1 (PH1) and hyperoxaluria, sponsored by Alnylam Pharmaceuticals. Primary endpoint: Change in plasma oxalate AUC between dialysis sessions (Cohort A). Started Jul 2019; status: active.
02
Drugs
lumasiran
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)hyperoxaluria
Beyond the preview
Go deeper on 2019-001346-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001346-17.